ArticleInvestigative ophthalmology & visual science2008
Modeling of corneal and retinal pharmacokinetics after periocular drug administration.
Article in Investigative ophthalmology & visual science, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 77 citations in OpenAlex.
- Efficacy of systemic diclofenac sodium on intravitreal concentration.International ophthalmology · 2018Trial
- Quantitative systems pharmacology of the eye: Tools and data for ocular QSP.CPT: pharmacometrics & systems pharmacology · 2023Review
- Successful regression of newly formed corneal neovascularization by subconjunctival injection of bevacizumab in patients with chemical burns.Frontiers in medicine · 2023Article
- Elastic Fibers/Fabrics for Wearables and Bioelectronics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Controlling the Adsorption and Release of Ocular Drugs in Metal-Organic Frameworks: Effect of Polar Functional Groups.Inorganic chemistry · 2022Article
- Ocular Fluid Mechanics and Drug Delivery: A Review of Mathematical and Computational Models.Pharmaceutical research · 2021Review
- Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.Drug delivery and translational research · 2021Review
- Effect of Poly(L-lysine) and Heparin Coatings on the Surface of Polyester-Based Particles on Prednisolone Release and Biocompatibility.Pharmaceutics · 2021Article
- Efficacy of systemic administration of riboflavin on a rabbit model of corneal alkali burn.Scientific reports · 2020Article
- Sustained and targeted episcleral delivery of celecoxib in a rabbit model of retinal and choroidal neovascularization.International journal of retina and vitreous · 2018Article
- Principles of pharmacology in the eye.British journal of pharmacology · 2017Review
- Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2016Article
- Prediction of passive drug permeability across the blood-retinal barrier.Pharmaceutical research · 2014Article
- Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.Progress in retinal and eye research · 2013Review
- Inhibition of corneal neovascularization with the combination of bevacizumab and plasmid pigment epithelium-derived factor-synthetic amphiphile INTeraction-18 (p-PEDF-SAINT-18) vector in a rat corneal experimental angiogenesis model.International journal of molecular sciences · 2013Article
- Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes.Experimental eye research · 2012Article
- Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids.Drug metabolism and disposition: the biological fate of chemicals · 2011Article
- Recent advances in ophthalmic drug delivery.Therapeutic delivery · 2010Review
- Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes.Expert opinion on drug delivery · 2010Review
- Measurement and modeling of diffusion kinetics of a lipophilic molecule across rabbit cornea.Pharmaceutical research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeTo develop pharmacokinetics models to describe the disposition of small lipophilic molecules in the cornea and retina after periocular (subconjunctival or posterior subconjunctival) administration.
methodsCompartmental pharmacokinetics analysis was performed on the corneal and retinal data obtained after periocular administration of 3 mg of celecoxib (a selective COX-2 inhibitor) to Brown Norway (BN) rats. Berkeley Madonna, a differential and difference equation-based modeling software, was used for the pharmacokinetics modeling. The data were fit to different compartment models with first-order input and disposition, and the best fit was selected on the basis of coefficient of regression and Akaike information criteria (AIC). The models were validated by using the celecoxib data from a prior study in Sprague-Dawley (SD) rats. The corneal model was also fit to the corneal data for prednisolone at a dose of 2.61 mg in albino rabbits, and the model was validated at two other doses of prednisolone (0.261 and 26.1 mg) in these rabbits. Model simulations were performed with the finalized model to understand the effect of formulation on corneal and retinal pharmacokinetics after periocular administration.
resultsCelecoxib kinetics in the BN rat cornea can be described by a two-compartment (periocular space and cornea, with a dissolution step for periocular formulation) model, with parallel elimination from the cornea and the periocular space. The inclusion of a distribution compartment or a dissolution step for celecoxib suspension did not lead to an overall improvement in the corneal data fit compared with the two-compartment model. The more important parameter for enhanced fit and explaining the apparent lack of an increase phase in the corneal levels is the inclusion of the initial leak-back of the dose from the periocular space into the precorneal area. The predicted celecoxib concentrations from this model also showed very good correlation (r = 0.99) with the observed values in the SD rat corneas. Similar pharmacokinetics models explain drug delivery to the cornea in rat and rabbit animal models. Retinal pharmacokinetics after periocular drug administration can be explained with a four-compartment (periocular space, choroid-containing transfer compartment, retina, and distribution compartment) model with elimination from the periocular space, retina, and choroid compartment. Inclusion of a dissolution-release step before the drug is available for absorption or elimination better explains retinal t(max). Good fits were obtained in both the BN (r = 0.99) and SD (r = 0.99) rats for retinal celecoxib using the same model; however, the parameter estimates differed.
conclusionsCorneal and retinal pharmacokinetics of small lipophilic molecules after periocular administration can be described by compartment models. The modeling analysis shows that (1) leak-back from the site of administration most likely contributes to the apparent lack of an increase phase in corneal concentrations; (2) elimination via the conjunctival or periocular blood and lymphatic systems contributes significantly to drug clearance after periocular injection; (3) corneal pharmacokinetics of small lipophilic molecules can be explained by using similar models in rats and rabbits; and (4) although there are differences in some retinal pharmacokinetics parameters between the pigmented and nonpigmented rats, the physiological basis of these differences has yet to be ascertained.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.